Company: PETVW
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001493152-25-011967
Chunk: 36

Company: PetVivo Holdings, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 36
---
, and proteoglycans such as heparin. Since these are naturally-occurring in
the body, we believe they have an enhanced biocompatibility with living tissues compared to synthetic biomaterials such as those based
upon alpha-hydroxy polymers (e.g. PLA, PLGA, and the like), polyacrylamides, and other “natural” biomaterials that may lack
the multiple proteins incorporated into our biomaterials. These proprietary protein-based biomaterials are similar to the body’s
tissue thus allowing integration and tissue repair in long-term implantation in certain applications.

Our
initial product, Spryng®, is a veterinary medical device designed to help reinforce and/or augment articular cartilage
tissue for the management of lameness and other joint related afflictions, such as osteoarthritis, in horses and companion animals. Spryng®
is an intra-articular injectable product of biocompatible and insoluble particles that are slippery, wet-permeable, durable, and resilient
to enhance the force cushioning function of the synovial fluid and cartilage. The particles mimic natural cartilage in composition, structure,
and hydration. Multiple joints can be treated simultaneously. Our particles are comprised of collagen, elastin, and heparin, similar
components found in natural cartilage. These particles show an effectiveness to reinforce and/or augment the cartilage, which enhances
the functionality of the joint (e.g. provide cushion or shock-absorbing features to the joint and to provide joint lubricity).

Osteoarthritis,
a common inflammatory joint disease in both dogs and horses, is a chronic, progressive, degenerative joint disease that is caused by
a loss of synovial fluid and/or the deterioration of joint cartilage. Osteoarthritis affects approximately 14 million dogs and 1 million
horses in the $11 billion companion animal veterinary care and product sales market.

Despite
the market size, veterinary clinics and hospitals have very few treatments and/or drugs for use in treating osteoarthritis in dogs, horses,
and other pets. As there is no cure for osteoarthritis, current solutions treat symptoms, but do not manage the cause. The current treatment
for osteoarthritis in dogs generally consists of the use of nonsteroidal anti-inflammatory drugs (or “NSAIDs”) which are
approved to alleviate pain and inflammation but present the potential for side effects relating to gastrointestinal, kidney, and